No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Pharmaceuticals
Sinphar Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the production, processing, selling, and trading of various medicines, chinese medicines, medical cosmetic products and nutrients in Taiwan, Mainland China, Vietnam, Indonesia, and internationally. It operates through three segments: Pharmaceuticals, Healthy Food, and Others. The company offers pharmaceutical products, including antineoplastic, ophthalmic, ENT, oral, respiratory system, dermatology, analgesic and NSAIDs, metabolic and nutrient, gastrointestinal, and other products; and healthy food under the Sinphar, DailyCare, Migus, YouBest, and SynCoreBio brands. It also provides moisturizer repair essence, anti aging cream, renewable oi, and UV defence cream under the DYNASKIN brand; serum, revitalizing cream, hygiene, sunblock, sunscreen, and lightening tables under the Yestuner brand; and shower gel and hair shampoo. In addition, the company is involved in the provision of testing and development, as well as product design and manufacturing services. The company was incorporated in 1977 and is based in Yilan City, Taiwan.
www.sinphar.comNo one on the platform currently holds 1734.TW.
No tracked institution reports a position in 1734.TW as of their last filing.
No one on the platform has traded 1734.TW yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 9.0% | — | — | — | ||
| Rev. Growth % | 7.0% | 7.1% | ||||
| Profit Margin % | 10.8% | 7.9% | 4.2% | |||
| Free Cash Flow Margin % | 11.4% | 6.1% | 0.7% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $2.2B | — | $0.10 | $0.10–$0.10 | — | 1 |
| 2027 | $2.2B | -0.1% | $0.06 | $0.06–$0.06 | — | 1 |
| 2028 | $2.3B | +6.9% | $0.09 | $0.09–$0.09 | — | 1 |
| 2029 | $3.1B | +33.8% | $1.47 | $1.47–$1.47 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 6 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-05-08 | $0.44 | $0.39 | -11.5% |
| 2026-03-12 | $0.38 | $0.54 | +41.6% |
| 2025-11-11 | $0.40 | $0.44 | +8.8% |
| 2025-08-12 | $0.40 | $0.38 | -6.0% |
| 2025-05-09 | $0.39 | $0.62 | +60.5% |
| 2025-03-06 | $0.45 | $0.45 | +0.2% |
| $8.94 |
| +2.88% |
| $6.4B |
| — |
| 4167.TWOSavior Lifetec Corp. | $19.10 | +0.26% | $6.3B | — |
| 4174.TWOOBI Pharma, Inc. | $26.45 | +1.73% | $3.5B | — |
Source: Financial Modeling Prep · peers by sector/industry